/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-10-01 18:03:392025-10-02 02:20:56iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-08-24 18:43:312025-08-24 18:50:58iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-05-05 19:01:572025-05-06 12:38:54iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-21 09:06:012025-03-21 09:06:01iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-11 19:35:012025-03-11 19:35:01iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-01-08 19:08:512025-01-09 16:28:06iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-05-07 05:00:362024-05-07 08:06:38iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-04-04 08:00:252024-04-04 08:03:08iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-03-05 19:31:452024-03-05 19:33:00iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2023-12-12 18:17:352023-12-13 08:07:51iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506
